ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
2.920
+0.240 (8.96%)
Jun 24, 2025, 12:55 PM - Market open
ADC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 75.82 | 70.84 | 69.56 | 209.91 | 33.92 | - | Upgrade
|
| Revenue Growth (YoY) | 10.49% | 1.84% | -66.86% | 518.89% | - | - | Upgrade
|
| Cost of Revenue | 115.13 | 115.58 | 129.66 | 189.76 | 159.4 | 141.82 | Upgrade
|
| Gross Profit | -39.32 | -44.75 | -60.1 | 20.15 | -125.48 | -141.82 | Upgrade
|
| Selling, General & Admin | 83 | 85.91 | 105.89 | 143.49 | 136.24 | 77.23 | Upgrade
|
| Operating Expenses | 86.19 | 85.91 | 105.89 | 143.49 | 136.24 | 77.23 | Upgrade
|
| Operating Income | -125.51 | -130.65 | -165.99 | -123.34 | -261.72 | -219.05 | Upgrade
|
| Interest Expense | -49.95 | -50.21 | -46.33 | -36.73 | -18.34 | -4.93 | Upgrade
|
| Interest & Investment Income | 11.38 | 12.27 | 10.54 | 2.57 | 0.07 | 0.83 | Upgrade
|
| Earnings From Equity Investments | -0.86 | -1.54 | -5.53 | -10.08 | -6.67 | 24.37 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.13 | -0.08 | -0.05 | -0.11 | 0.05 | -0.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 15.39 | 12.54 | 6.4 | 52.91 | 35.11 | -46.4 | Upgrade
|
| EBT Excluding Unusual Items | -149.67 | -157.68 | -200.95 | -114.79 | -251.51 | -245.75 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -0.22 | Upgrade
|
| Other Unusual Items | - | - | - | -42.11 | - | - | Upgrade
|
| Pretax Income | -149.67 | -157.68 | -200.95 | -156.9 | -251.51 | -245.96 | Upgrade
|
| Income Tax Expense | 0.17 | 0.17 | 39.11 | 0.23 | -21.48 | 0.33 | Upgrade
|
| Net Income | -149.84 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | Upgrade
|
| Net Income to Common | -149.84 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | Upgrade
|
| Shares Outstanding (Basic) | 103 | 97 | 82 | 78 | 77 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 97 | 82 | 78 | 77 | 65 | Upgrade
|
| Shares Change (YoY) | 25.77% | 18.91% | 4.55% | 1.83% | 17.33% | 32.73% | Upgrade
|
| EPS (Basic) | -1.45 | -1.62 | -2.94 | -2.01 | -3.00 | -3.77 | Upgrade
|
| EPS (Diluted) | -1.45 | -1.62 | -2.94 | -2.01 | -3.00 | -3.77 | Upgrade
|
| Free Cash Flow | -136.67 | -124.7 | -121.9 | -139 | -236.81 | -169.53 | Upgrade
|
| Free Cash Flow Per Share | -1.32 | -1.28 | -1.49 | -1.78 | -3.09 | -2.59 | Upgrade
|
| Gross Margin | -51.86% | -63.17% | -86.40% | 9.60% | - | - | Upgrade
|
| Operating Margin | -165.54% | -184.44% | -238.63% | -58.76% | -771.65% | - | Upgrade
|
| Profit Margin | -197.64% | -222.83% | -345.11% | -74.86% | -678.20% | - | Upgrade
|
| Free Cash Flow Margin | -180.27% | -176.04% | -175.25% | -66.22% | -698.20% | - | Upgrade
|
| EBITDA | -124.16 | -129.32 | -164.8 | -122.28 | -260.75 | -218.23 | Upgrade
|
| EBITDA Margin | -163.76% | -182.56% | -236.92% | -58.26% | - | - | Upgrade
|
| D&A For EBITDA | 1.35 | 1.33 | 1.19 | 1.06 | 0.97 | 0.82 | Upgrade
|
| EBIT | -125.51 | -130.65 | -165.99 | -123.34 | -261.72 | -219.05 | Upgrade
|
| EBIT Margin | -165.54% | -184.44% | -238.63% | -58.76% | - | - | Upgrade
|
| Revenue as Reported | 75.82 | 70.84 | 69.56 | 209.91 | 33.92 | - | Upgrade
|
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.